Is NCT05263206 recruiting in Savannah, GA?

Yes, NCT05263206 is currently recruiting participants at its Savannah, GA location. This chronic itching clinical trial is actively enrolling qualified participants.

How do I join the chronic itching clinical trial in Savannah?

To join this clinical trial in Savannah, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Savannah clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Chronic Itching Clinical Trial in Savannah, GA

About This Chronic Itching Study in Savannah

The main objective of the study is to assess efficacy and safety of dupilumab given up to 24 weeks in adults with CPUO. This is a master protocol which includes 2 parallel-treatment, double-blind, 2- arm Phase 3 staggered studies of similar design (Study A and Study B) in male and female participants aged 18 to 90 years with CPUO. Study B design was to be adapted based on the results of Study A. For both Study A and B, after an up-to-4-week screening period, participants with severe pruritus (

Sponsor: Sanofi

Who Can Participate

Inclusion Criteria

Participant must be 18 (or the legal age of consent in the jurisdiction in which the study is taking place) to 90 years of age inclusive, at the time of signing the informed consent.

Participants with chronic pruritus for at least 6 months before the screening visit.

Chronic pruritus considered of unknown origin as assessed by the investigator at baseline (excluding chronic pruritus secondary to dermatological or systemic conditions, of neuropathic or psychogenic origin or secondary to drugs).

Chronic pruritus must affect at least 2 of the following body areas: legs, arms, or trunk.

History of insufficient control of the chronic pruritus with prior treatment.

Participants should receive optimal treatment for concomitant conditions that could impact pruritus (eg, diabetes, iron deficiency).

Participants must have a history of severe itch and a worst itch score of ≥7 at screening on the WI-NRS (score scale ranges from 0 to 10; higher score indicates worse itch) and Patient Global Impression of Severity (PGIS) of pruritus scored "severe" at screening.

Participants must have an average worst itch score of ≥7 in the 7 days prior to run-in visit and in the 7 days prior to Day 1 on the WI-NRS.

Participants scored "severe" in the PGIS of pruritus on Day 1.

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the patient's participation in the study.

Patients with active tuberculosis or non-tuberculous mycobacterial infection, or a history of incompletely treated tuberculosis, unless it is well documented by a specialist that the participant has been adequately treated and can now start treatment with a biologic agent.

Diagnosed with, suspected of, or at high risk of endoparasitic infection, and/or use of antiparasitic drug within 2 weeks before the screening visit.

HIV infection.

Severe renal failure (dialysis).

Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, or antifungals within 2 weeks before the run-in visit.

Known or suspected immunodeficiency.

Active malignancy or history of malignancy within 5 years before the baseline visit, except completely treated in situ carcinoma of the cervix and completely treated and resolved non metastatic squamous or basal cell carcinoma of the skin.

History of hypersensitivity or intolerance to non-sedative antihistamines.

Participation in prior dupilumab clinical study or have been treated with commercially available dupilumab. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Savannah?

Yes, this clinical trial (NCT05263206) has an active research site in Savannah, GA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Itching Treatment Options in Savannah, GA

If you're searching for chronic itching treatment options in Savannah, GA, this clinical trial (NCT05263206) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Savannah research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced chronic itching specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic itching clinical trials near you to find additional studies recruiting in your area.

Chronic Itching Clinical Trial in Savannah, GA

Expert Care in Savannah

IRB Approved

No-Cost Care

Apply for This Savannah Location

Why Participate?

Simple Process